Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plinabulin and Pegfilgrastim for Neutropenia in Multiple Myeloma After AHCT
NCT05130827Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2021
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plinabulin in neutropenia, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Average duration of absolute neutropenia at 1 year. Started Dec 2021; status: active, not recruiting.
02
Drugs
plinabulin
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT05130827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05130827.